PT  - JOURNAL ARTICLE
AU  - Mosley, Mary
ED  - Del Prato, Stefano
TI  - ENDURE: Alogliptin Effective and Safe through 2 Years
DP  - 2013 Dec 01
TA  - MD Conference Express
PG  - 22--22
VI  - 13
IP  - 17
4099  - http://mdc.sagepub.com/content/13/17/22.1.short
4100  - http://mdc.sagepub.com/content/13/17/22.1.full
AB  - The Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Subjects With Type 2 Diabetes Mellitus study [ENDURE; NCT00856284] showed that there were greater reductions in the primary endpoint of least square mean change from baseline in HbA1C at 104 weeks with two doses of the DPP-4 inhibitor alogliptin compared with the sulfonylurea glipizide.